If you have read that Ozempic or Wegovy can trigger depression or suicidal thoughts, a new academic review says the evidence does not back it up.
Researchers at New Mexico State University and the University of Nevada, Las Vegas pulled together five years of clinical trial, real-world and regulatory data on GLP-1 drugs.
Their conclusion was that the drug class is not tied to a meaningful rise in serious psychiatric harm in the general treated population.
The integrative review, published July 30, 2026 in the journal Diabetology, covered evidence on the widely used GLP-1 receptor agonists, including semaglutide (the active ingredient in Novo Nordisk's Ozempic and Wegovy), liraglutide (Saxenda) and tirzepatide (the active ingredient in Eli Lilly's Zepbound and Mounjaro).
Also read: Running a HEPA air filter at home may sharpen your brain in just one month
The authors describe GLP-1 drugs as a cornerstone treatment now used by tens of millions of patients for type 2 diabetes and obesity.
Where the fear came from
Early concern grew from spontaneous reports flagged in adverse-event databases, plus viral anecdotes online.
Those reporting systems are useful early-warning tools, but they cannot separate a real drug effect from background rates of mood problems in people who are already more likely to experience them.
Depression is more common in people with type 2 diabetes than in the general population, the review notes, which can inflate the signal when large numbers of new patients start a medication.
Also read: Training your mind for 8 weeks may improve your blood pressure and inflammation
Regulators looked into the same signal. In January 2024, the US Food and Drug Administration reported that its preliminary review of adverse-event reports, clinical trials and observational data did not find evidence that GLP-1 drugs cause suicidal thoughts or actions.
The European Medicines Agency ran a parallel investigation.
What the FDA concluded
Earlier this year, the agency went a step further.
Based on a meta-analysis of 91 clinical trials with 107,910 participants and a retrospective study of roughly 2.2 million adults through its Sentinel monitoring system, the FDA asked drug makers on January 13, 2026 to remove suicidal ideation and behavior language from the labels of Saxenda, Wegovy and Zepbound.
Also read: How regular dancing can benefit the brain
The FDA said GLP-1 users did not have an increased risk of suicidal ideation or behavior compared with control groups.
The academic review lands on the same picture. Studies following millions of patients found no rise in psychiatric risk tied to GLP-1 treatment, the authors write, and several large analyses have actually pointed the other way.
A Nature Medicine analysis of more than 240,000 people with overweight or obesity, cited during the FDA process, found a lower risk of new suicidal ideation among adults prescribed semaglutide than among those on other weight-loss drugs.
Where closer monitoring still makes sense
The review does not give every patient a blanket all-clear. The authors flag that people already taking antidepressants or benzodiazepines showed stronger reporting signals for suicidal ideation, which they say warrants closer monitoring rather than avoidance of the drugs.
Also read: 8 early warning signs of heart failure most people write off as being out of shape
Individualized follow-up matters most for anyone with a pre-existing psychiatric condition.
For readers already taking a GLP-1 drug, the practical message is straightforward. Do not stop treatment on the basis of an online claim about mood.
If you notice new or worsening depression, anxiety or thoughts of self-harm while on any medication, contact your doctor.
Also read: One daily bowl of oatmeal may lower your LDL cholesterol, and the FDA agrees
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.